Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. - Wikidata - wikimedia - TriplyDB

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33343522

about

Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia Efforts to prevent and halt autoimmune beta cell destruction.Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.Does chemotherapy modify the immune surveillance of hematological malignancies?Incidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adults Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes.Myelodysplasia--therapeutic response to novel therapy and the need for new diagnostic groups.Oxidative stress and the myelodysplastic syndromes.How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes Immune dysregulation in myelodysplastic syndrome.Myelodysplastic syndrome with erythroid hypoplasia Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.Novel therapies for myelodysplastic syndromes.Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes.Emerging drugs for the treatment of myelodysplastic syndrome.DNA micro-array analysis of myelodysplastic syndrome.Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.Treatment strategies in myelodysplastic syndromes.Management of myelodysplastic syndromes: 2008 update.Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Update on the therapy for myelodysplastic syndrome.Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood.Immunological derangement in hypocellular myelodysplastic syndromes.Current and future management options for myelodysplastic syndromes.Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions.Management of lower-risk myelodysplastic syndromes: the art and evidence.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome.

P2860

Q30235355-A2CCE48D-5DAB-45DD-80B3-E509287708D3 Q33365126-C1FE8DDC-E447-46EA-A3A8-E16B8A05BE75 Q33370159-33A8FE1B-7D6D-4AC7-818D-59F85253BD58 Q33379562-284A2F78-0BD2-47E5-BC0D-9C2E63B77AD3 Q33399233-F7E8E669-8BF6-475B-8A27-9E301395188B Q33702157-32787EEE-30B6-4F9E-A5F6-FE417298CBA8 Q33796552-025BAE67-3319-46EA-832F-1F36D4C54BC0 Q34077363-8C8A972E-319E-4F60-AF8E-0F893F3C43FB Q34098328-FC32F278-A5AF-4302-AEF7-3EF6B2AA4692 Q34223517-6EAD7F4A-FA78-4D80-81D1-F605F952FB6B Q34501072-68286D46-928B-4DAF-A76D-C112B32978F4 Q34635314-5191B49B-09F9-4B64-A56B-609CA1514930 Q35134995-5ED354F8-996F-4BC9-B2E3-60DBD2EDCD62 Q35140206-B76043F6-3E07-4C34-BC0F-E4B9F3BCAF52 Q35202854-A40DADCD-E753-457E-AD00-146B66B3DA20 Q35567932-C93437E9-7BAC-4603-9A18-55F3723323C5 Q35588400-F699D4F6-778D-42F5-96BF-863CDD46EDDE Q35657367-46C79FC4-3422-4DAF-9888-559BE6687FC2 Q35828771-14DFE7A4-6B30-4655-AF89-DB021B213A9C Q35829958-E743ADF4-EE13-41FF-9A74-062E558B18AC Q35847917-6987E683-A7A1-4172-A5C6-324DB89A69C1 Q35996506-C07E8E40-9FA5-4263-B622-DC8455070701 Q36219655-14DD5CE2-5A3A-4454-8917-BF520C06097F Q36328414-A24F31F9-162C-4A5B-9222-DDCF60431AA0 Q36445351-49385570-0DA3-4B67-8BCE-ED90A5F209A8 Q37079916-665F9E29-A7FA-448C-93F2-882F2B86C2DD Q37108489-B290342C-EB8A-4563-A6B3-6AF8933945C8 Q37222206-041BFAB3-6C09-48F3-BEB9-95D752F83D0F Q37263146-DA63AF86-4D17-4C7E-884A-D2308F16DCC8 Q37385953-E3FE463C-C20E-4CEE-B0BF-30F4DC91DD8C Q37584833-80D94206-F471-4CC5-BA78-D557A527B39E Q37676271-6712992B-F329-407A-8587-85EADE95ED8D Q37724605-CEBDFA48-63FF-4C82-883C-95C0B60C57C8 Q37771015-0072258F-E537-4F66-97DF-FD48CED45EAF Q37820432-00EA780B-E8E0-404B-B326-1CBB160A4A2A Q37858436-21479652-0C55-499E-AF10-1DE60C0851AB Q37864686-50070345-9F6B-4B00-981C-B700BC14510A Q37937816-1F21C48A-AD38-4F33-BFF1-1B621D449E30 Q38046783-2C4A2714-3974-409E-B2BC-B62CDABB1BE9 Q38463964-174D6383-89B8-4719-804D-FEF568CD9A1B

P2860

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33343522

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Antithymocyte globulin for tre ...... ith myelodysplastic syndromes.

@ast

Antithymocyte globulin for tre ...... ith myelodysplastic syndromes.

@en

type

label

Antithymocyte globulin for tre ...... ith myelodysplastic syndromes.

@ast

Antithymocyte globulin for tre ...... ith myelodysplastic syndromes.

@en

prefLabel

Antithymocyte globulin for tre ...... ith myelodysplastic syndromes.

@ast

Antithymocyte globulin for tre ...... ith myelodysplastic syndromes.

@en

P1433

Q33343522-B7B3EF0D-68E0-4F3D-AE65-762F6A47CA0E

P1476

Q33343522-19B244AE-2D98-4D24-8037-EBCA2753E850

P2093

Q33343522-09705001-D497-4919-BEB7-726BFB368456

Q33343522-30766264-6E42-4AC1-8730-0A9BDC6CA680

Q33343522-67B9A6D9-2251-4ED2-9DC5-96138560F564

Q33343522-717F5B8B-A7C4-498D-8D4A-0C3022A660A9

Q33343522-A03E4AB7-AE2A-4464-8E1D-B70857E2DCA9

Q33343522-A707C8E2-9AA0-49F7-B7FA-2575380B408A

Q33343522-A87679C6-D7CD-45B2-A58B-DFCFC770C416

Q33343522-C0D5F1EE-9910-4AB6-87B9-EAA36999F21E

Q33343522-F547F39F-BA7F-428C-881B-8E8E7BA596A6

P304

Q33343522-C9C51F18-0972-4F8F-9055-9D8F2269D899

P31

Q33343522-9B86F004-AAEB-4484-85B2-43904FCBAC8E

P356

Q33343522-BB0E73C5-8738-430A-8741-2B3A58AEFEB0

P407

Q33343522-A742A3CF-F2FE-4E39-AA5C-C566D212B740

P433

Q33343522-306FF690-4D07-40BA-ACA8-B24035F79470

P478

Q33343522-0B4864D2-ED32-4049-9543-CCF2C9C6D57A

P50

Q33343522-CDD0A2C4-AEE0-4324-B4EB-B2AB57523090

P577

Q33343522-1CD5EDC1-EC63-463F-BE8A-140C98E946CB

P698

Q33343522-C49DCFCD-9AF8-46BC-8541-91C93AD8985F

P921

Q33343522-8DDD59C7-10A5-46E0-A142-E4C07DE44A4B

P356

0003-4819-137-3-200208060-00007

P1433

Annals of Internal Medicine

P1476

Antithymocyte globulin for tre ...... ith myelodysplastic syndromes.

@en

P2093

A John Barrett

http://www.w3.org/2001/XMLSchema#string

Eric Leifer

http://www.w3.org/2001/XMLSchema#string

Erkut Bahceci

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Molldrem

http://www.w3.org/2001/XMLSchema#string

Johnson Liu

http://www.w3.org/2001/XMLSchema#string

Mary Rivera

http://www.w3.org/2001/XMLSchema#string

Neal S Young

http://www.w3.org/2001/XMLSchema#string

Riotoro Nakamura

http://www.w3.org/2001/XMLSchema#string

Yogen Saunthararajah

http://www.w3.org/2001/XMLSchema#string

P304

156-163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-137-3-200208060-00007

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Cynthia E Dunbar

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12160363

http://www.w3.org/2001/XMLSchema#string

P921